Puma Biotechnology Inc (NYSE:PBYI) Earns “Buy” Rating from Stifel Nicolaus

Puma Biotechnology Inc (NYSE:PBYI)‘s stock had its “buy” rating reaffirmed by Stifel Nicolaus in a research note issued on Monday. They presently have a $105.00 price target on the biopharmaceutical company’s stock. Stifel Nicolaus’ price objective indicates a potential upside of 20.62% from the stock’s previous close.

Other equities analysts also recently issued reports about the stock. Leerink Swann began coverage on shares of Puma Biotechnology in a research note on Monday. They issued an “outperform” rating and a $115.00 price target on the stock. Citigroup Inc. raised shares of Puma Biotechnology to a “buy” rating and set a $105.00 target price on the stock in a research report on Sunday, May 28th. Royal Bank of Canada increased their target price on shares of Puma Biotechnology from $60.00 to $88.00 and gave the stock a “sector perform” rating in a research report on Tuesday, June 6th. J P Morgan Chase & Co reissued an “overweight” rating and set a $89.00 target price on shares of Puma Biotechnology in a research report on Tuesday, June 6th. Finally, Zacks Investment Research raised shares of Puma Biotechnology from a “hold” rating to a “buy” rating and set a $89.00 target price on the stock in a research report on Thursday, June 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $89.75.

Shares of Puma Biotechnology (NYSE:PBYI) traded down 0.86% during trading on Monday, reaching $86.30. The company had a trading volume of 136,610 shares. The stock’s 50-day moving average price is $70.29 and its 200-day moving average price is $44.73. The stock’s market capitalization is $3.19 billion. Puma Biotechnology has a 12 month low of $28.35 and a 12 month high of $92.00.

Puma Biotechnology (NYSE:PBYI) last released its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($1.97) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($2.06) by $0.09. Equities analysts forecast that Puma Biotechnology will post ($8.50) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Puma Biotechnology Inc (NYSE:PBYI) Earns “Buy” Rating from Stifel Nicolaus” was reported by WKRB News and is the property of of WKRB News. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at https://www.wkrb13.com/markets/2285377/puma-biotechnology-inc-nysepbyi-earns-buy-rating-from-stifel-nicolaus.html.

In other Puma Biotechnology news, major shareholder Adage Capital Partners Gp, L.L sold 507,128 shares of Puma Biotechnology stock in a transaction on Monday, June 5th. The shares were sold at an average price of $87.84, for a total transaction of $44,546,123.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders sold 1,990,088 shares of company stock valued at $157,553,113. 22.70% of the stock is currently owned by company insiders.

A number of large investors have recently modified their holdings of PBYI. Bank of Montreal Can acquired a new stake in shares of Puma Biotechnology during the first quarter valued at approximately $195,000. Alambic Investment Management L.P. acquired a new stake in shares of Puma Biotechnology during the first quarter valued at approximately $201,000. Parametric Portfolio Associates LLC acquired a new stake in shares of Puma Biotechnology during the first quarter valued at approximately $257,000. Weiss Multi Strategy Advisers LLC acquired a new stake in shares of Puma Biotechnology during the first quarter valued at approximately $335,000. Finally, Legal & General Group Plc boosted its stake in shares of Puma Biotechnology by 2.8% in the first quarter. Legal & General Group Plc now owns 9,297 shares of the biopharmaceutical company’s stock valued at $346,000 after buying an additional 249 shares during the period. 80.98% of the stock is currently owned by hedge funds and other institutional investors.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Analyst Recommendations for Puma Biotechnology (NYSE:PBYI)

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2285377/puma-biotechnology-inc-nysepbyi-earns-buy-rating-from-stifel-nicolaus.html

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.